Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 415648, 11 pages
http://dx.doi.org/10.1155/2015/415648
Review Article

Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China

Received 13 October 2014; Revised 16 April 2015; Accepted 16 April 2015

Academic Editor: Dimitris S. Ladas

Copyright © 2015 Xiaoqun Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Calvet, M.-J. R. Lázaro, P. Lehours, and F. Mégraud, “Diagnosis and epidemiology of Helicobacter pylori infection,” Helicobacter, vol. 18, supplement 1, pp. 5–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. P. Blankfield, A. Zullo, C. Hassan et al., “Helicobacter pylori infection and the development of gastric cancer,” The New England Journal of Medicine, vol. 346, no. 1, pp. 65–67, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Y. Graham and L. Fischbach, “Helicobacter pylori infection,” The New England Journal of Medicine, vol. 363, no. 6, pp. 595–596, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current European concepts in the management of Helicobacter pylori infection—the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG),” European Journal of Gastroenterology and Hepatology, vol. 9, no. 1, pp. 1–2, 1997. View at Google Scholar · View at Scopus
  5. K. M. Fock, P. Katelaris, K. Sugano et al., “Second Asia-pacific consensus guidelines for helicobacter pylori infection,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587–1600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Megraud, S. Coenen, A. Versporten et al., “Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption,” Gut, vol. 62, no. 1, pp. 34–42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. de Francesco, F. Giorgio, C. Hassan et al., “Worldwide H. pylori antibiotic resistance: a systematic review,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409–414, 2010. View at Google Scholar · View at Scopus
  8. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. T. J. Borody, G. Pang, A. R. Wettstein et al., “Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 4, pp. 481–488, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Gisbert, M. Castro-Fernandez, A. Perez-Aisa et al., “Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 8, pp. 941–947, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. Gisbert and X. Calvet, “Review article: rifabutin in the treatment of refractory Helicobacter pylori infection,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 2, pp. 209–221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration,” BMJ, vol. 339, p. b2700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” BMJ, vol. 339, Article ID b2535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Fiorini, N. Vakil, A. Zullo et al., “Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection,” Clinical Gastroenterology and Hepatology, vol. 11, no. 5, pp. 507–510, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Navarro-Jarabo, N. Fernández, F. L. Sousa et al., “Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection,” BMC Gastroenterology, vol. 7, article 31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Miehlke, K. Hansky, W. Schneider-Brachert et al., “Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 2, pp. 395–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Qasim, S. Sebastian, O. Thornton et al., “Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 1, pp. 91–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. P. Gisbert, J. L. Gisbert, S. Marcos, R. Moreno-Otero, and J. M. Pajares, “Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 10, pp. 1469–1474, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Perri, V. Festa, R. Clemente et al., “Randomized study of two ‘rescue’ therapies for Helicobacter pylori-infected patients after failure of standard triple therapies,” American Journal of Gastroenterology, vol. 96, no. 1, pp. 58–62, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Gisbert, J. L. Gisbert, S. Marcos, and J. M. Pajares, “Empirical Helicobacter pylori ‘rescue’ therapy after failure of two eradication treatments,” Digestive and Liver Disease, vol. 36, no. 1, pp. 7–12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. P. Gisbert, J.-L. Gisbert, S. Marcos, I. Jimenez-Alonso, R. Moreno-Otero, and J. M. Pajares, “Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 4, pp. 346–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Toracchio, S. Capodicasa, D. B. Soraja, L. Cellini, and L. Marzio, “Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin,” Digestive and Liver Disease, vol. 37, no. 1, pp. 33–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. P. Gisbert, X. Calvet, L. Bujanda, S. Marcos, J. L. Gisbert, and J. M. Pajares, “‘Rescue‘ therapy with rifabutin after multiple Helicobacter pylori treatment failures,” Helicobacter, vol. 8, no. 2, pp. 90–94, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. P. González Carro, F. Pérez Roldán, A. De Pedro Esteban et al., “Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments,” Journal of Gastroenterology and Hepatology, vol. 22, no. 1, pp. 60–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Veldhuyzen van Zanten, S. Desai, L. Best et al., “Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection,” Canadian Journal of Gastroenterology, vol. 24, no. 5, pp. 303–306, 2010. View at Google Scholar · View at Scopus
  26. F. Perri, V. Festa, R. Clemente, M. Quitadamo, and A. Andriulli, “Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens,” Alimentary Pharmacology and Therapeutics, vol. 14, no. 3, pp. 311–316, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Bock, H. Koop, N. Lehn, and M. Heep, “Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience,” Journal of Clinical Gastroenterology, vol. 31, no. 3, pp. 222–225, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Zullo, V. de Francesco, G. Manes, G. Scaccianoce, F. Cristofari, and C. Hassan, “Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 2, pp. 131–134, 2010. View at Google Scholar · View at Scopus
  29. D. Van der Poorten and P. H. Katelaris, “The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice,” Alimentary Pharmacology and Therapeutics, vol. 26, no. 11-12, pp. 1537–1542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Perri, V. Festa, R. Clemente et al., “Rifabutin-based treatment as ‘rescue therapy’ for H. Pylori infected patients after failure of standard regimens: a pilot study,” Gastroenterology, vol. 114, supplement 1, p. A257, 1998. View at Google Scholar
  31. J. P. Gisbert, M. Castro-Fernandez, A. P. Aisa et al., “Fourth-line rescue therapy with rifabutin in patients with three H. pylori eradication failures,” Gastroenterology, vol. 146, no. 5, p. S-395, 2014. View at Google Scholar
  32. T. Borody, G. Agrawal, J. Campbell, and eatl, “Rescue H. pylori therapy in the clinical setting,” American Journal of Gastroenterology, vol. 107, p. S594, 2012. View at Google Scholar
  33. B. S. Moon, H. C. Lim, Y. C. Lee et al., “Efficacy of rifabutin based triple therapy including high dose ppi and amoxicillin for third line rescue therapy of Helicobacter pylori,” Helicobacter, vol. 17, p. 105, 2012. View at Google Scholar
  34. K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, and J. Chipponi, “Methodological index for non-randomized studies (Minors): development and validation of a new instrument,” ANZ Journal of Surgery, vol. 73, no. 9, pp. 712–716, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. W. M. Wong, O. Gu, S. K. Lam et al., “Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 4, pp. 553–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Miehlke, W. Schneider-Brachert, C. Kirsch et al., “One-week once-daily triple therapy with esomeprazole, Moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin,” Helicobacter, vol. 13, no. 1, pp. 69–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Basu, N. Shah, M. D. Rahaman et al., “omeprazole, alinia, and doxycycline therapy for prior treatment failure Helicobacter pylori population: a randomized, open-label clinical pilot study road trial,” American Journal of Gastroenterology, vol. 108, article S49, 2013. View at Google Scholar
  38. P. Basu, N. J. Shah, K. Mittimani et al., “Rifabutin, omeprazole, alinia and doxycycline therapy for prior treatment failure Helicobacter pylori (HP) population—a randomized open label clinical pilot study-road trial,” Gastroenterology, vol. 144, no. 5, p. S336, 2013. View at Google Scholar
  39. S. P. Yun, H. G. Seon, C. S. Ok et al., “Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori,” Gut and Liver, vol. 6, no. 4, pp. 452–456, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. M. M. D'Elios, E. Silvestri, G. Emmi, T. Barnini, and D. Prisco, “Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen,” Expert Review of Gastroenterology and Hepatology, vol. 6, no. 4, pp. 437–439, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Burgos-Santamaria, A. G. McNicholl, J. Gisbert et al., “Su1169 Empirical rescue therapy after H. pylori treatment failure. A 15-year single center study of 1,000 patients,” Gastroenterology, vol. 146, no. 5, p. S-394, 2014. View at Publisher · View at Google Scholar
  42. M. H. Jeong, J. W. Chung, S. J. Lee et al., “Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori,” The Korean Journal of Gastroenterology, vol. 59, no. 6, pp. 401–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. P. Gisbert, M. Castro-Fernandez, A. P. Aisa et al., “Fourth-line rescue therapy with rifabutin in patients with three H. pylori eradication failures,” Gastroenterology, vol. 140, no. 5, p. S878, 2011. View at Google Scholar
  44. J. P. Gisbert, M. Castro-Fernandez, A. P. Aisa et al., “Fourth-line rescue therapy with rifabutin in patients with three H. Pylori eradication failures,” Gastroenterology, vol. 144, no. 5, p. S334, 2013. View at Google Scholar
  45. S. Miehlke, K. Hansky, W. Schneider-Brachert et al., “Seven-day triple therapy with esomeprazole, rifabutin and amoxicillin is effective in eradicating Helicobacter pylori resistant to both metronidazole and clarithromycin—a prospective, randomized multicenter trial,” Gastroenterology, vol. 124, supplement 1, no. 4, p. A359, 2003. View at Publisher · View at Google Scholar
  46. S. Miehlke, K. Hansky, W. Schneider-Brachert et al., “One-week triple therapy with esomeprazole, rifabutin and amoxicillin is effective for eradication of Helicobacter pylori resistant to both metronidazole and clarithromycin,” Gastroenterology, vol. 128, no. 4, p. A64, 2005. View at Google Scholar
  47. K. M. Fock, P. Katelaris, K. Sugano et al., “Second Asia-Pacific consensus guidelines for Helicobacter pylori infection,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587–1600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. M. Smith, R. B. Haider, H. O'Connor et al., “Practical treatment of Helicobacter pylori: a balanced view in changing times,” European Journal of Gastroenterology & Hepatology, vol. 26, no. 8, pp. 819–825, 2014. View at Google Scholar
  50. R. Piccolomini, G. Di Bonaventura, C. Picciani, F. Laterza, J. Vecchiet, and M. Neri, “In vitro activity of clarithromycin against intracellular Helicobacter pylori,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 5, pp. 1568–1571, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. A. O'Connor, I. Taneike, A. Nami et al., “Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre,” Irish Journal of Medical Science, vol. 182, no. 4, pp. 693–695, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. M. Biernat, E. Poniewierka, J. Błaszczuk et al., “Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland,” Archives of Medical Science, vol. 10, no. 3, pp. 505–509, 2014. View at Publisher · View at Google Scholar
  53. D. Y. Graham, Y.-C. Lee, and M.-S. Wu, “Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence,” Clinical Gastroenterology and Hepatology, vol. 12, no. 2, pp. 177–186, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. J. K. Akada, M. Shirai, K. Fujii, K. Okita, and T. Nakazawa, “In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1072–1076, 1999. View at Google Scholar · View at Scopus
  55. G. Rossi, “An update on the antibiotic therapy of tuberculosis,” Recenti Progressi in Medicina, vol. 90, no. 5, pp. 241–243, 1999. View at Google Scholar
  56. J.-Y. Wu, J.-M. Liou, and D. Y. Graham, “Evidence-based recommendations for successful Helicobacter pylori treatment,” Expert Review of Gastroenterology and Hepatology, vol. 8, no. 1, pp. 21–28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Gao, H.-P. Xiao, Z.-Y. Hu, Z.-L. Cui, J.-M. Lu, and X.-N. Shen, “Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains,” Zhonghua Jie He He Hu Xi Za Zhi, vol. 35, no. 5, pp. 333–335, 2012. View at Google Scholar · View at Scopus
  58. F. B. Jamieson, J. L. Guthrie, A. Neemuchwala, O. Lastovetska, R. G. Melano, and C. Mehaffy, “Profiling of rpoB mutations and MICs for rifampin and rifabutin in mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 52, no. 6, pp. 2157–2162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Apseloff, “Severe neutropenia among healthy volunteers given rifabutin in clinical trials,” Clinical Pharmacology and Therapeutics, vol. 74, no. 6, pp. 591–592, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Jetton, J. G. Gaviria, T. F. Patterson, and D. A. Johnson, “Rifabutin-associated uveitis in an immunocompetent individual with Mycobacterium simiae,” Canadian Journal of Ophthalmology, vol. 44, no. 4, pp. 468–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. W. M. Smith, M. G. Reddy, K. A. Hutcheson, R. J. Bishop, and H. N. Sen, “Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia,” Journal of Ophthalmic Inflammation and Infection, vol. 2, no. 3, pp. 149–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. J.-Y. Chien, S.-T. Chien, S.-Y. Huang, and C.-J. Yu, “Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 3, pp. 790–796, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Pochat-Cotilloux, F. De Bats, A. M. Nguyen et al., “Rifabutin-associated bilateral uveitis: a case report,” Journal Français d'Ophtalmologie, vol. 37, no. 8, pp. e115–e117, 2014. View at Publisher · View at Google Scholar
  64. D. E. Griffith, B. A. Brown, W. M. Girard, and R. J. Wallace Jr., “Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease,” Clinical Infectious Diseases, vol. 21, no. 3, pp. 594–598, 1995. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Apseloff, G. Foulds, L. LaBoy-Goral, E. Kraut, and J. Vincent, “Severe neutropenia caused by recommended prophylactic doses of rifabutin,” The Lancet, vol. 348, no. 9028, p. 685, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. F. di Mario, L. G. Cavallaro, and C. Scarpignato, “‘Rescue’ therapies for the management of Helicobacter pylori infection,” Digestive Diseases, vol. 24, no. 1-2, pp. 113–130, 2006. View at Publisher · View at Google Scholar · View at Scopus